Linked Life Data

19262586

Source:http://linkedlifedata.com/resource/pubmed/id/19262586

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-3-5
pubmed:abstractText
Harrison et al. have attempted to validate Part II of the Unified Parkinson's Disease Rating Scale (UPDRS II) as a medication-independent measure of disease progression. The authors collected cross-sectional data from a cohort of 888 patients with idiopathic Parkinson disease, and they found a robust association between UPDRS II scores and disease duration. Other variables considered were the patients' levodopa status, age at disease onset, and scores on UPDRS I, II and III. The results suggest that a single UPDRS II measurement might be a good indicator of progression at a given time point, irrespective of the current disease-related circumstances. This concept is attractive in its simplicity and patient-centeredness. However, this evidence came from a single-center, retrospective study, the statistical model was constructed using a nonvalidated surrogate as an independent variable, and no external replication was conducted. Until further confirmation, therefore, Harrison et al.'s proposal can only be considered to be a working hypothesis.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Mar
pubmed:issn
1745-8358
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
130-1
pubmed:year
2009
pubmed:articleTitle
Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?
pubmed:affiliation
Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisbon, Portugal. crissampaio@mail.telepac.pt
pubmed:publicationType
Journal Article, Comment